We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ondine Biomedical Inc (OBI) NPV

Sell:8.00p Buy:8.25p 0 Change: No change
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.00p
Buy:8.25p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.00p
Buy:8.25p
Change: No change
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Ondine raising £8.5m to fund US clinical trial

    1 November 2024 10:47

    (Sharecast News) - Ondine Biomedical announced a proposed minimum £8.5m fundraising through a placing and subscription of new shares on Friday, priced at 8.5p each, to support the US phase three clinical...

  • Ondine Biomedical gets UAE approval for Steriwave

    18 October 2024 12:04

    (Sharecast News) - Ondine Biomedical announced on Friday that it has received regulatory approval to market its 'Steriwave' nasal decolonisation technology in the United Arab Emirates.

  • Ondine Biomedical's Steriwave added to NHS Supply Chain

    21 June 2024 13:14

    (Sharecast News) - Life science company Ondine Biomedical announced on Friday that its 'Steriwave' nasal photodisinfection treatment was now available through the NHS Supply Chain.

  • Ondine reports significant financial growth

    24 April 2024 15:09

    (Sharecast News) - Ondine Biomedical reported significant growth in a trading update on Wednesday, with revenues doubling to $1.2m in 2023, driven by expanded hospital deployments of 'Steriwave'.

  • Ondine Biomedical assessing Steriwave with Yorkshire partners

    5 March 2024 13:50

    (Sharecast News) - Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium...

  • Ondine raises $3.6m to help commercialise Steriwave

    13 December 2023 14:43

    (Sharecast News) - Life sciences company Ondine Biomedical has successfully raised CAD 4.91m ($3.62m), it announced on Wednesday, bolstering its efforts to commercialise its photodisinfection technology...

  • Ondine reports strong research findings from Canadian hospitals

    23 October 2023 12:15

    (Sharecast News) - Ondine Biomedical announced ground-breaking research findings from Vancouver General and University of British Columbia (UBC) Hospitals in British Columbia, Canada, on Monday, after they...

  • Ondine announces expanded Canadian availability of Steriwave

    13 October 2023 16:15

    (Sharecast News) - Life sciences company Ondine Biomedical announced the expansion of the availability of its Steriwave nasal photo disinfection technology on Friday across various hospitals in Canada.

  • Ondine disinfection tech to be used at another Canadian hospital

    7 August 2023 10:57

    (Sharecast News) - Ondine Biomedical announced on Monday that it is joining forces with Canada's Kelowna General Hospital (KGH) in a pilot targeting the prevention of hospital-acquired infections (HAIs).

  • Ondine Biomedical reports first-quarter progress

    17 April 2023 12:06

    (Sharecast News) - Life sciences company Ondine Biomedical reported a number of operational highlights in a first-quarter update on Monday, including clinical developments for US market approval, additional...

  • Ondine Biomedical upbeat on photodisinfection study

    17 January 2023 17:30

    (Sharecast News) - Ondine Biomedical said on Tuesday that a new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT) using its proprietary methylene blue-based...

  • Ondine reports success in MRSA clinical trial

    2 December 2022 12:34

    (Sharecast News) - Ondine Biomedical reported full results from its phase two 'BENEFIT-PDT' clinical trial on Friday, which met its primary endpoint of bacterial load reduction after nasal...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2024. All rights reserved.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.